GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vanucizumab   Click here for help

GtoPdb Ligand ID: 9132

Synonyms: RG-7221 | RG7221 | RO5520985
Compound class: Antibody
Comment: Vanucizumab is an investigational bi-specific monoclonal antibody, with potential anti-neoplastic activity being developed by Hoffmann-La Roche [1-2]. Vanucizumab simultaneously targets angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST seuqence analysis reveals 100% matches with peptide sequences claimed in patent US8945552 and likely identify XMab1 and XMab2 as candidates for vanucizumab [1].
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
9950 vanucizumab
Synonyms Click here for help
RG-7221 | RG7221 | RO5520985
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 500
Reactome Drug Reactome logo R-ALL-9679469
Reactome Reaction Reactome logo R-HSA-9679477
Other databases
GtoPdb PubChem SID 315661217
Search PubMed clinical trials vanucizumab
Search PubMed titles vanucizumab
Search PubMed titles/abstracts vanucizumab